This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
EPE Aktienübersicht
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Epizyme, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.42 |
| 52 Week High | US$4.90 |
| 52 Week Low | US$0.35 |
| Beta | -0.42 |
| 1 Month Change | -2.74% |
| 3 Month Change | 178.43% |
| 1 Year Change | -69.20% |
| 3 Year Change | -88.07% |
| 5 Year Change | -88.07% |
| Change since IPO | -92.92% |
Aktuelle Nachrichten und Updates
Recent updates
Aktionärsrenditen
| EPE | DE Biotechs | DE Markt | |
|---|---|---|---|
| 7D | -3.4% | -2.5% | -2.8% |
| 1Y | -69.2% | -24.1% | 0.5% |
Rendite im Vergleich zur Industrie: EPE underperformed the German Biotechs industry which returned -2.5% over the past year.
Rendite vs. Markt: EPE underperformed the German Market which returned -20.5% over the past year.
Preisvolatilität
| EPE volatility | |
|---|---|
| EPE Average Weekly Movement | 23.5% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.6% |
Stabiler Aktienkurs: EPE's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: EPE's weekly volatility has increased from 17% to 23% over the past year.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2007 | 250 | Grant Bogle | www.epizyme.com |
Epizyme, Inc.'s Grundlagenzusammenfassung
| EPE grundlegende Statistiken | |
|---|---|
| Marktanteil | €241.38m |
| Gewinn(TTM) | -€202.60m |
| Umsatz(TTM) | €51.70m |
4.7x
Kurs-Umsatz-Verhältnis-1.2x
Kurs-Gewinn-VerhältnisIst EPE zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| EPE Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$53.01m |
| Kosten der Einnahmen | US$20.28m |
| Bruttogewinn | US$32.73m |
| Sonstige Ausgaben | US$240.47m |
| Umsatz | -US$207.73m |
Zuletzt gemeldete Gewinne
Jun 30, 2022
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.23 |
| Bruttomarge | 61.75% |
| Nettogewinnspanne | -391.88% |
| Schulden/Eigenkapital-Verhältnis | -1,148.4% |
Wie hat sich EPE auf lange Sicht entwickelt?
Historische Performance und Vergleiche